Franklin Resources Inc. Purchases 292,421 Shares of Oruka Therapeutics, Inc. $ORKA

Franklin Resources Inc. boosted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 40.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,012,968 shares of the company’s stock after purchasing an additional 292,421 shares during the quarter. Franklin Resources Inc. owned about 2.71% of Oruka Therapeutics worth $11,355,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Braidwell LP lifted its stake in shares of Oruka Therapeutics by 37.0% in the first quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock valued at $16,133,000 after buying an additional 424,750 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after acquiring an additional 354,821 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in Oruka Therapeutics in the 1st quarter valued at about $2,505,000. Affinity Asset Advisors LLC boosted its stake in Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock valued at $5,595,000 after purchasing an additional 176,664 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Oruka Therapeutics during the 1st quarter valued at about $1,362,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Trading Down 6.9%

Shares of Oruka Therapeutics stock opened at $28.36 on Friday. The business’s fifty day simple moving average is $25.25 and its 200 day simple moving average is $17.58. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $31.00. The firm has a market capitalization of $1.37 billion, a P/E ratio of -10.09 and a beta of -0.30.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.01. Analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on ORKA. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research note on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective for the company. Guggenheim assumed coverage on Oruka Therapeutics in a report on Monday, October 27th. They set a “buy” rating and a $60.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. BTIG Research raised their price objective on Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.14.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.